VRPX vs. CWBR, SRNE, NMTR, TRVN, NAVB, EVFM, VIRX, ATXI, BPTSY, and BIOR
Should you be buying Virpax Pharmaceuticals stock or one of its competitors? The main competitors of Virpax Pharmaceuticals include CohBar (CWBR), Sorrento Therapeutics (SRNE), 9 Meters Biopharma (NMTR), Trevena (TRVN), Navidea Biopharmaceuticals (NAVB), Evofem Biosciences (EVFM), Viracta Therapeutics (VIRX), Avenue Therapeutics (ATXI), Biophytis (BPTSY), and Biora Therapeutics (BIOR). These companies are all part of the "pharmaceutical products" industry.
Virpax Pharmaceuticals vs.
CohBar (NASDAQ:CWBR) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.
In the previous week, CohBar's average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.
CohBar's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.
Virpax Pharmaceuticals has a consensus price target of $75.00, indicating a potential upside of 34,783.72%. Given Virpax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Virpax Pharmaceuticals is more favorable than CohBar.
CohBar has a beta of 1.39, meaning that its share price is 39% more volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500.
2.5% of CohBar shares are owned by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. 6.5% of CohBar shares are owned by insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
CohBar received 15 more outperform votes than Virpax Pharmaceuticals when rated by MarketBeat users. Likewise, 72.00% of users gave CohBar an outperform vote while only 60.00% of users gave Virpax Pharmaceuticals an outperform vote.
Summary
CohBar beats Virpax Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
Get Virpax Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Virpax Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:VRPX) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy VRPX Stock Free VRPX Stock Alerts